Juvenile Macular Degeneration Market: Key Growth Factors and Opportunity Analysis by 2027
Market Highlights
Eye care has become one of the important aspects of medicine
due to the continuous development of new therapies and availability of
technologically advanced devices for eye care. Furthermore, the prevalence of
eye disease is found to be increasing for all ages. Macular degeneration
diseases such as Best disease and Stargardt disease are found to be highly
prevalent among the children. Market players are now focusing on the
development of novel therapies such as stem cell therapy to reduce the
supply-demand gap in the market. Eye care supplement act as a protective
measure whose demand is found to be increasing in the developing countries
across the globe. Additionally, increasing demand for early diagnosis and
treatment is boosting the market growth.
Global Juvenile
Macular Degeneration (Stargardt Disease) market is expected to grow at a
CAGR of 7.2% during the forecast period 2017-2023.
Segmentation
The global juvenile macular degeneration (Stargardt Disease)
market is segmented on the basis of diagnosis, devices and end users.
On the basis of diagnosis, the market is segmented into
Fluroscein Angiography (FA), Fundus Autofluorescence (FAF), Optical Coherence
Tomography (OCT), and Electroretinography (ERG).
On the basis of devices, the market is segmented into
magnifying spectacles, magnifiers, reading telescope.
On the basis of end users, the market is segmented into
hospitals & eye clinics, and research & academic institutes.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/4935
Regional Analysis
The global juvenile macular degeneration market consists of
four major regions: the Americas, Europe, Asia Pacific, and the Middle East and
Africa.
America holds the largest market share in the juvenile
macular degeneration market owing to increasing prevalence of eye diseases in
the U.S. and Canada. Demand for eye care supplements, availability of specialty
services further fuels the growth of the market. According to World Health
Organization (WHO), in 2014, worldwide 285 million people were visually
impaired in which 246 have low vision and 39 million are completely blind.
Moreover, the North America region accounted for USD 163.23 Million in 2016.
The European juvenile macular degeneration market accounted
for 32.7% market share in 2016. In Europe, Germany, the U.K, and France are the
largest contributors to the market owing to the availability of funds for
research, and extensive research and development activities in ophthalmology.
The development of novel therapies and other treatment options for juvenile
macular degeneration also fuel the growth of the market.
In Asia Pacific, India, and China are the fastest developing
regions in the market owing to an overall demand for early diagnostic and
treatment services, and increasing expenditure on primary care services across
Asia Pacific. Rising awareness about
degeneration among the children and available treatment options also influence
the growth of the market. The growth of the market is also influenced by
improvement in the delivery of care in the number of healthcare institutes such
as hospitals, specialty clinics, diagnostic center, and others.
The Middle East & Africa exhibit steady but positive
growth owing to low technology penetration in developing regions of Africa, and
increasing demand for diagnostics services in developing regions. In the Middle
East, the United Arab Emirates accounts for the largest market share for
macular degeneration.
Access Report Details @ https://www.marketresearchfuture.com/reports/juvenile-macular-degeneration-market-4935
Key Players
Some of key the players in the market are Acucela Inc. (U.S.), Alkeus Pharmaceuticals
Inc. (U.S.), Astellas Pharma Inc. (Japan), ProQR Therapeutics NV (Netherland),
Sanofi (France), Bayer HealthCare (Germany), F. Hoffmann-La Roche (Switzerland), Copernicus Therapeutics Inc.
(U.S.), Grupo Ferrer Internacional SA (U.S.), Iris Pharma (U.S.), Nemus
Bioscience Inc (U.S.), Ophthotech Corp (U.S.), Iconic Therapeutics (U.S.),
Adverum Biotechnologies (U.S.), PanOptica (U.S.), RXi Pharmaceuticals (U.S.),
Neurotech Pharmaceuticals (U.S.)
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment